The breast cancer somatic 'muta-ome': tackling the complexity.

Abstract excerpt

Acquired somatic mutations are responsible for approximately 90% of breast tumours. However, only one somatic aberration, amplification of the HER2 locus, is currently used to define a clinical subtype, one that accounts for approximately 10% to 15% of breast tumours. In recent years, a number of mutational profiling studies have attempted to further identify clinically relevant mutations. While these studies...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Neoplasms
• Share to Genes, Tumor Suppressor
• Share to Genetic Predisposition to Disease